FCR chemoimmunotherapy is most effective in the IGVH mutated, non-17p deletion chronic lymphocytic leukemia (CLL) patient subgroup. With the advent of novel drugs in the field however, Nitin Jain, MD, from the MD Anderson Cancer Center, Houston, TX, believes that this therapy could be improved upon. In this interview, recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, he discusses the rationale behind, and results from, his trial (NCT02629809) investigating the effect of iFCG, a combination therapy including ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab. Boasting minimal residual disease negativity rates of over 90%, this treatment option has huge potential.
iFCG yields unprecedented MRD negativity in CLL
